Mary Joseph, DO
Family Medicine · Oklahoma City, OKNPI 1336554492
Payments from drug & device makers
Across 386 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$859
- AbbVie$823
- Pfizer$772
- Boehringer Ingelheim$597
- AstraZeneca$589
- Novo Nordisk$494
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,12399%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 62 | $859 |
| AbbVie(2 entities) | 41 | $823 |
| Pfizer | 56 | $772 |
| Boehringer Ingelheim | 36 | $597 |
| AstraZeneca | 29 | $589 |
| Novo Nordisk | 37 | $494 |
| GSK | 30 | $341 |
| Amgen | 18 | $274 |
| Abbott | 10 | $194 |
| Astellas Pharma US Inc | 8 | $137 |
| Sanofi-aventis U.S. LLC | 7 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $104 |
| Bayer | 5 | $86 |
| Shield Therapeutics Inc | 2 | $78 |
| Exact Sciences | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Novartis | 3 | $57 |
| Merck | 4 | $52 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Kyowa Kirin, Inc. | 3 | $48 |
| Corcept Therapeutics | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Vyera Pharmaceuticals, LLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$6,173 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $82,166 |
| TrulicityDulaglutide | 60 | $75,797 |
| EliquisApixaban | 53 | $59,682 |
| JardianceEmpagliflozin | 31 | $45,498 |
| MounjaroTirzepatide | 33 | $44,140 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $24,225 |
| JanuviaSitagliptin Phosphate | 18 | $16,774 |
| TradjentaLinagliptin | 13 | $11,430 |
| FarxigaDapagliflozin Propanediol | 15 | $9,369 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $8,835 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,712 |
| MyrbetriqMirabegron | 13 | $7,939 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,386 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,585 |
| PremarinEstrogens, Conjugated | 23 | $5,328 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $859 | $119,93793 claims |
| Novo NordiskOzempic | $494 | $82,16675 claims |
| PfizerEliquis, Premarin, Paxlovid | $772 | $66,35887 claims |
| Boehringer IngelheimJardiance, Tradjenta | $597 | $56,92844 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $341 | $29,81031 claims |
| MerckJanuvia | $52 | $16,77418 claims |
| AstraZenecaFarxiga | $589 | $9,36915 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $7,93913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.